Imlunestrant

Imlunestrant
Clinical data
Pronunciation/ˌɪmlʊˈnɛstrənt/
IM-luu-NES-trənt
Trade namesInluriyo
Other namesLY3484356, LY-3484356
AHFS/Drugs.comMonograph
MedlinePlusa625104
License data
Routes of
administration
By mouth
Drug classEstrogen receptor antagonist
ATC code
  • None
Legal status
Legal status
Identifiers
  • (5R)-5-[4-[2-[3-(Fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H24F4N2O3
Molar mass524.516 g·mol−1
3D model (JSmol)
  • C1C(CN1CCOC2=CC=C(C=C2)[C@@H]3C4=C5C=CC(=CC5=NC=C4C6=C(O3)C=C(C=C6)C(F)(F)F)O)CF
  • InChI=1S/C29H24F4N2O3/c30-13-17-15-35(16-17)9-10-37-21-5-1-18(2-6-21)28-27-23-8-4-20(36)12-25(23)34-14-24(27)22-7-3-19(29(31,32)33)11-26(22)38-28/h1-8,11-12,14,17,28,36H,9-10,13,15-16H2/t28-/m1/s1
  • Key:UVBQMXOKKDCBJN-MUUNZHRXSA-N

Imlunestrant, sold under the brand name Inluriyo, is an anti-cancer medication used for the treatment of breast cancer. It is an estrogen receptor antagonist. It is used as the salt, imlunestrant tosylate. It is taken by mouth. It was developed by Eli Lilly and Company.

The most common adverse events and laboratory abnormalities include decreased hemoglobin, musculoskeletal pain, decreased calcium, decreased neutrophils, increased AST, fatigue, diarrhea, increased ALT, increased triglycerides, nausea, decreased platelets, constipation, increased cholesterol, and abdominal pain.

Imlunestrant was approved for medical use in the United States in September 2025, and in the European Union in January 2026.